Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-26T09:20:32.942Z Has data issue: false hasContentIssue false
  • English
  • Français

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States

Published online by Cambridge University Press:  01 January 2021

Roojin Habibi ,
Line Guénette ,
Joel Lexchin ,
Ellen Reynolds ,
Mary Wiktorowicz  and
Barbara Mintzes
Get access Rights & Permissions [Opens in a new window]

Abstract

Diverse legal and regulatory measures are used internationally to control the information provided during pharmaceutical sales visits. Little is known about the comparative effectiveness of these measures however. We analyzed the perceptions of regulators, pharmaceutical industry officials, health professionals, and consumer respondents concerning these approaches in Canada, France, and the United States using an empirical realist interests-based approach. Interviews focused on the aims and effectiveness of regulation, barriers and enablers to regulation and suggestions for improvement. An alignment was found in North America regulator and industry respondents' satisfaction with the status quo and their view that further intervention is unfeasible and unnecessary. Health professionals generally expressed a lack of confidence in the impact of regulations on sales visit information while consumer advocates voiced their disappointment in both regulators and health professionals for their failure to counteract the influence of pharmaceutical marketing. Regulator and industry respondents in France differed from their North American counterparts in their willingness to increase and diversify the scope of regulatory interventions. As the first international comparison of regulatory experiences in this sector, the findings highlight the universal need for more focused and inclusive discussions among groups about how to tailor regulations to achieve public health goals.

Type
Independent Articles
Information
Journal of Law, Medicine & Ethics , Volume 44 , Issue 4: Health Reform: Assessing the Affordable Care Act and Moving Forward , Winter 2016 , pp. 602 - 615
Copyright
Copyright © American Society of Law, Medicine and Ethics 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gagnon, M. and Lexchin, J., “The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States,” PLoS Medicine, 5, no.1 (2008): e1–e5.Google Scholar
Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., and Vitry, A. I., “Information From Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review,” PLoS Medicine 7, no. 10 (2010): e1000352.Google Scholar
Id.Google Scholar
Dewees, D. N., Mathewson, G. F., and Trebilcock, M., “The Rationale for Government Regulation of Quality,” in Dewees, D. N., ed., The Regulation of Quality: Product, Services, Workplaces and the Environment (Toronto: Butterworks, 1983): at 1–26.Google Scholar
Davis, P., “Pharmaceuticals and Public Policy: Learning from the New Zealand Experience,” Health Policy 24, no. 3 (1993): 259–272.Google Scholar
Baume, P., A Question of Balance: Report on the Future of Drug Evaluation in Australia (Canberra: Commonwealth of Australia, 1991).Google Scholar
Trebilcock, M., Waverman, L., and Pritchard, J. R. S., “Markets for Regulation,” in Government Regulation: Issues and Alternatives (Ottawa: Ontario Economic Council, 1978); M.N.G. Dukes, “The Importance of Adverse Reactions in Drug Regulation,” Drug Safety 5, no. 1 (1990): 3-6.Google Scholar
World Health Organization, Ethical Criteria for Medicinal Drug Promotion, available at <http://apps.who.int/medicinedocs/documents/whozip08e/whozip08e.pdf> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
Dukes, M. N. G., “The Industry as a Source of Information, Persuasion and Education,” in The Law and Ethics of the Pharmaceutical Industry (Amsterdam: Elsevier, 2005): at 183–214.Google Scholar
Ratanawijitrasin, S. and Wondemagegnehu, E., Effective Drug Regulation, World Health Organization available at <http://apps.who.int/medicinedocs/pdf/s2300e/s2300e.pdf> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
Stryer, D. and Bero, L., “Characteristics of Materials Distributed by Drug Companies: An Evaluation of Appropriateness,” Journal of General Internal Medicine 11, no.10 (1996): 575–583.Google Scholar
Prescrire International, “15 Years of Monitoring and One Simple Conclusion: Don't Expect Sales Representatives to Help Improve Healthcare Quality,” La Revue Prescrire 15, no. 84 (2006): 154–159.Google Scholar
Sernyak, M. and Rosenheck, R., “Experience of VA Psychiatrists with Pharmaceutical Detailing of Antipsychotic Medications,” Psychiatric Services 58, no. 10 (2007): 1292–1296.CrossRefGoogle Scholar
Othman, N., Vitry, A. I., Roughead, E. E., Ismail, S. B., and Omar, K., “Medicines Information Provided by Pharmaceutical Representatives: A Comparative Study in Australia and Malaysia,” BMC Public Health 10, no. 1 (2010): 743–754.Google Scholar
Mintzes, B., Lexchin, J., Sutherland, J. M., Beaulieu, M., Wilkes, M. S., Durrieu, G., and Ritchie, J., “Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States,” Journal of General Internal Medicine 28, no. 10 (2013): 1368–1375.Google Scholar
Strang, D. G., Gagnon, M., Molloy, D. W., Darzins, P., Etchells, E., Bédard, M., and Davidson, W., “Development of a Standardized, Comprehensive‘ Ideal Drug Detail’,” Canadian Journal of Clinical Pharmacology 8, no. 2 (2000): 73–77.Google Scholar
Pharmaceutical Advertising Advisory Board, Code of Advertising Acceptance (Pickering, ON: 2013), available at <http://www.paab.ca/resources/pdfs/PAAB%20Code%20Eng%20Nov%2023%202012.pdf> (last visited October 10, 2016); Code de la santé publique [C.S.P.][Public Health Code] Art. L5122-2; Federal Food, Drug, and Cosmetic Act 21 U.S.C. § 352(a), (f)(1), (n); 21 C.F.R. § 202.1(e)(5)(i) (2015).+(last+visited+October+10,+2016);+Code+de+la+santé+publique+[C.S.P.][Public+Health+Code]+Art.+L5122-2;+Federal+Food,+Drug,+and+Cosmetic+Act+21+U.S.C.+§+352(a),+(f)(1),+(n);+21+C.F.R.+§+202.1(e)(5)(i)+(2015).>Google Scholar
Wiktorowicz, M. E., “Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France,” Journal of Health Politics, Policy and Law 28, no.4 (2003).Google Scholar
Davis, C. and Abraham, J., Unhealthy Pharmaceutical Regulation (London: Palgrave MacMillan, 2013): at 19.Google Scholar
See Mintzes, supra note 15.Google Scholar
Food and Drugs Act R.S.C. 1985, c. F-27, s. 9.Google Scholar
Health Canada, “Requirements for Regulatory Advertising,” available at <http://www.hc-sc.gc.ca/dhp-mps/advert-publicit/index-eng.php> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
See Pharmaceutical Advertising Advisory Board, supra note 17.Google Scholar
Innovative Medicines Canada, Code of Ethical Practices (Ottawa: 2016), available at <http://innovativemedicines.ca/wp-content/uploads/2015/06/IMC_Code_EN.pdf> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
Council for Continuing Pharmaceutical Education, The Accreditation Course, available at <http://www.ccpe-cfpc.com/en/our_courses/accreditation.html> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
House of Commons Standing Committee on Health, Opening the Medicines Cabinet: First Report on Health Aspects of Prescription Drugs (Ottawa: 2004), available at <http://www.parl.gc.ca/content/hoc/Committee/373/HEAL/Reports/RP1282198/healrp01/healrp01-e.pdf> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
See Code de la santé publique, supra note 17.Google Scholar
Comité économique des produits de santé and Les entreprises du médicament, Charte de l'information par demarchage ou prospection visant à la promotion des médicaments [Charter on the promotion of medicines through provided by solicitation or sales visit] (Paris: 2015), available at <http://social-sante.gouv.fr/IMG/pdf/CHARTE_CEPS_LEEM_promotion_vm_signee.pdf> (last visited October 10, 2016). (last visited October 10, 2016).' href=https://scholar.google.com/scholar?q=Comité+économique+des+produits+de+santé+and+Les+entreprises+du+médicament,+Charte+de+l'information+par+demarchage+ou+prospection+visant+à+la+promotion+des+médicaments+[Charter+on+the+promotion+of+medicines+through+provided+by+solicitation+or+sales+visit]+(Paris:+2015),+available+at++(last+visited+October+10,+2016).>Google Scholar
Association pour la gestion de la formation des visiteurs médicaux, Devenir VM [Becoming a pharmaceutical sales representative], available at <http://www.agvm.fr/candidat/processus.php3> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
Haute Autorité de Santé, Référentiel de certification de l'activité d'information par démarchage ou prospection visant à la promotion des médicaments [Standard of Certification on the promotion of medicine through information provided by solitication or salves visit] (Paris: 2016), available at <http://www.has-sante.fr/portail/jcms/c_2619852/fr/referentiel-decertification-ip-mars-2016> (last visited October 10, 2016). (last visited October 10, 2016).' href=https://scholar.google.com/scholar?q=Haute+Autorité+de+Santé,+Référentiel+de+certification+de+l'activité+d'information+par+démarchage+ou+prospection+visant+à+la+promotion+des+médicaments+[Standard+of+Certification+on+the+promotion+of+medicine+through+information+provided+by+solitication+or+salves+visit]+(Paris:+2016),+available+at++(last+visited+October+10,+2016).>Google Scholar
See Federal Food Drug and Cosmetic Act, supra note 17.Google Scholar
United States Government Accountability Office, Prescription Drugs: FDA's Oversight of Promotion of Drugs for Off-Label Uses (Washington: 2008), GAO-08-835, available at <http://www.gao.gov/assets/280/278832.pdf> (last visited October 10, 2016). (last visited October 10, 2016).' href=https://scholar.google.com/scholar?q=United+States+Government+Accountability+Office,+Prescription+Drugs:+FDA's+Oversight+of+Promotion+of+Drugs+for+Off-Label+Uses+(Washington:+2008),+GAO-08-835,+available+at++(last+visited+October+10,+2016).>Google Scholar
National Association of Pharmaceutical Sales Representatives, CNPR Pharmaceutical Sales Training Program, available at <http://www.napsronline.org/cnpr-pharmaceutical-sales-program/> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
United States Food and Drug Administration, Truthful Prescription Drug Advertising and Promotion, available at <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/DrugMarketingAdvertisingandCommunications/ucm209384.htm> (last visited October 10, 2016).+(last+visited+October+10,+2016).>Google Scholar
Nguyen, D., Seoane-Vazquez, E., Rodriguez-Monguio, R., and Montagne, M., “Changes in FDA Enforcement Activities Following Changes in Federal Administration: The Case of Regulatory Letters Released to Pharmaceutical Companies,” BMC Health Services Research 13, no. 1 (2013).Google Scholar
False Claims Act 31 U.S.C. § 3729-33.Google Scholar
Almashat, S. and Wolfe, S. M., Pharmaceutical Industry Criminal and Civil Penalties: An Update (Washington: Public Citizen, 2012), available at <http://www.citizen.org/hrg2073> (last visited October 10, 2016).Google Scholar
See Mintzes et al., supra note 15.Google Scholar
Id.Google Scholar
Mullard, A., “Mediator Scandal Rocks French Medical Community,” Lancet 377, no. 9769 (2011): 890–891.Google Scholar
Ritche, J. and Spencer, L., “Qualitative Data Analysis for Applied Policy Research,” in Bryman, A. and Burgess, R. G., eds., Analyzing Qualitative Data (London: Routledge, 1994): at 173–194.Google Scholar
Abraham, J., “Sociology of Pharmaceuticals Development and Regulation: A Realist Empirical Research Programme,” Sociology of Health and Illness 30, no. 6 (2008): 869–885.Google Scholar
See Ratanwijitrasin, supra note 10.Google Scholar
See Davis, supra note 19 at 11.Google Scholar
See Mintzes et al., supra note 15.Google Scholar
Wiktorowicz, M. and Deber, R., “Regulating Biotechnology: A Rational-Political Model of Policy Development,” Health Policy 40, no. 2 (1997): 115–138.Google Scholar
See Mintzes, supra note 15.Google Scholar
See Davis, supra note 19, at 11; Carpenter, D., “Corrosive Capture? The Dueling Forces of Autonomy and Industry Influence in FDA Pharmaceutical Regulation,” in Moss, D. and Carpenter, D., eds., Preventing Regulatory Capture (Boston: Cambridge University Press, 2015): at 152–172.Google Scholar
Lexchin, J. and Kawachi, I., “Voluntary Codes of Pharmaceutical Marketing: Controlling Promotion or Licensing Deception,” in Davis, P., ed., Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs (New York: Oxford University Press, 1996): 221–235.Google Scholar
Zetterqvist, A. V., Merlo, J., and Mulinari, S., “Complaints, Complainants and Rulings Regarding Drug Promotion in the United Kingdom and Sweden 2004-2012: A Quantitative and Qualitative Study of Pharmaceutical Industry Self-Regulation,” PLoS Medicine 12, no. 2 (2015): e1001785–e1001828.Google Scholar
See Almashat, supra note 37; Evans, D., “Special Report: Big Pharma's Crime Spree,” Bloomberg Markets (2009): 73–86.Google Scholar
Mascret, D., “Xavier Bertrand: Électrochoc dans le monde du médicament,” [Xavier Bertrand: Electric shock in the field of medicines], Tribunes de la santé 42, no. 1 (2014): 47–55.Google Scholar
See Gagnon, supra note 1.Google Scholar
Dukes, M. N. G., Braithwaite, J., and Moloney, J. P., Pharmaceuticals, Corporate Crime and Public Health (Cheltenham, UK: Edward Elgar, 2014).Google Scholar
Larkin, I., Ang, D., Avorn, J., and Kesselheim, A. S., “Restrictions on Pharmaceutical Detailing Reduced Off-Label Prescribing of Antidepressants and Antipyschotics in Children,” Health Affairs 33, no. 6 (2014): 1014–1023.Google Scholar
See Abraham, supra note 42.Google Scholar
Hancher, L., Regulating for Competition: Government, Law and the Pharmaceutical Industry in the United Kingdom and France (Oxford: Clarendon Press, 1990).Google Scholar
Clarke, J., Bainton, D., Lendvai, N., and Stubbs, P., eds., Making Policy Move: Towards a Politics of Translation and Assemblage (Chicago: University of Chicago Press, 2015).Google Scholar
See Davis, supra note 19, at 275.Google Scholar